

Personalised Cancer Medicine Flashcards 2025 Melanoma



Standard

BRAF v-600

Recommended

NRAS*
NTRK
PDL1**
C-KIT***
HLA-A*02:01****

*in cases BRAF negative

**for using combinations of anti-PD1 with anti-CTL4 or anti-LAG3

***in mucosal or acral melanoma or melanoma associated with sunlight

****in uveal melanoma

Currently not recommended

NRAS
GNAQ/GNA11
PTEN
MITF
CDKN2A
MHC-II
Tumor mutational burden

The **Standard** category is based on current treatment indications with approved funding by the Spanish National Health System

The **Recommended** category is based on current recommendations by EMEA and FDA

1. Amaral T, Ottaviano M, Arance A, et al; ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025 Jan;36(1):10-30. doi: 10.1016/j.annonc.2024.11.006.
2. European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics Update 2024. Garbe, Claus et al. European Journal of Cancer, Volume 215, 115152
3. Márquez-Rodas I, Muñoz Couselo E, Rodríguez Moreno JF, Arance Fernández AM, Berciano Guerrero MÁ, Campos Balea B, de la Cruz Merino L, Espinosa Arranz E, García Castaño A, Berrocal Jaime A. SEOM-GEM clinical guidelines for cutaneous melanoma (2023). Clin Transl Oncol. 2024 Nov;26(11):2841-2855. doi: 10.1007/s12094-024-03497-2. Epub 2024 May 15. PMID: 38748192; PMCID: PMC11467041



Cátedra de
Medicina Personalizada de Precisión

UAM Universidad Autónoma
de Madrid

